

Combination therapy of methotrexate and iguratimod for female patients with moderate to severe active rheumatoid arthritis and its impact on ovarian function

Zhang Jingzhou, Zhou Xiong and Kong Qing Xin*

Chongqing Chemical Industry Vocational College, Chongqing, China

Abstract: Rheumatoid arthritis is systemic inflammatory disease, presenting as symmetrical polyarthritis, mainly affecting hands and feet. Female patients with rheumatoid arthritis have also decreased fertility and premature ovarian failure. Methotrexate is used in treatment of rheumatoid arthritis. However, single treatment of Methotrexate is not ideal and often needs to be combined with other drugs like Iguratimod for intensive treatment of refractory rheumatoid arthritis. We aim to explore efficacy of combined use of MTX and IGU for female patients with rheumatoid arthritis and its impact on ovarian reserve function. Total 80 female patients with moderate to severe active rheumatoid arthritis were selected and randomly divided into MTX and MTX + IGU groups. The MTX + IGU group showed lower levels of IL-1 β , IL-6, IL-17, and TNF- α after treatment as compared to MTX group. The MTX + IGU group showed significantly higher level of AMH at the end of treatment. However, no statistical differences were observed in FSH, LH, E2 and AFC levels between the two groups. The combined therapy of MTX and IGU has better efficacy with less impact on ovarian function, even improving ovarian reserve function through effective control of rheumatoid inflammatory activity.

Keywords: Rheumatoid arthritis, methotrexate, iguratimod, ovarian function, inflammation.

INTRODUCTION

Rheumatoid arthritis (RA) is a common immune disease, with early symptoms of joint morning stiffness, pain, swelling, etc., and could develop into joint deformity as the disease progresses, resulting in the loss of normal joint function, seriously affecting the patient's daily work and life (Littlejohn *et al.*, 2018). With the focus on the reproductive health of RA patients, female RA patients were found to have decreased fertility and premature ovarian failure performance (Brouwer *et al.*, 2013). Clowse ME *et al* found that 578 women with RA had 1.5 times more infertility rates than the controls. A nationwide prospective cohort study of RA patients in the Netherlands showed that 42% women with RA have a time to pregnancy (TTP) of >12 months, significantly longer than the control group (Brouwer *et al.*, 2015). Ovarian reserve function refers to the quantity and quality of follicles stored in ovarium, which is necessary for the normal fertility function of women, and reflects the female fertility within a certain period of time. The decline of ovarian reserve function refers to the reduced ability to produce eggs and the quality of follicles, leading to weakened female fertility and sex hormone deficiency, and eventually developing to premature ovarian failure.

Methotrexate (MTX) is the “anchor drug” (Fraenkel *et al.*, 2021) for RA treatment, which has an immunosuppressive effect and could effectively prevent the abnormal activation of B cell *in vivo*, inhibit abnormal generation of cytokine and relieve related symptoms. However, some cases reflected that single treatment of MTX is not ideal

and often needed to be combined with other drugs. Iguratimod (IGU) (Mizutani *et al.*, 2021), as a new disease-modifying antirheumatic drug (DMARDs), is a new small molecule drug with anti-inflammatory and immunomodulatory properties, and a derivative of 7-methanesulfonylamino-6-phenoxychromones and is a chromone with two amide groups. IGU is a novel slow-acting antirheumatic drug, with both anti-inflammatory and immunomodulatory effects. It functions by: Inhibiting nuclear factor-B (NF-B) activation via interfering with the NF-B translocation from the cytoplasm to the nucleus, without affecting the degradation of Ikappa B α in LPS-stimulated THP-1 cells (human leukemia monocytic cell line) (Aikawa *et al.*, 2022); inhibiting the production of immunoglobulin and multiple inflammatory cytokines in B cells via PKC/Egr1/BLIMP1 axis (Tanaka *et al.*, 2003); inhibiting cell immunity by up regulating Treg cells to induce (Gan *et al.*, 2016); promoting bone formation, inhibiting bone resorption (Wang *et al.*, 2017) and preventing cartilage erosion, etc. Meanwhile, IGU is a derivative of nimesulide. It relieves the symptoms of RA patients by restraining the metabolism of prostaglandin E2, the metabolite of arachidonic acid, the release of bradykinin and the production of IL-1 and IL-6 (Nozaki *et al.*, 2021). Therefore, it is a new drug with both chronic anti-rheumatic function and NSAID (Nonsteroidal Anti-inflammatory Drugs) function. It was approved for treating RA in China and Japan in 2012 (Zheng *et al.*, 2018), and was recommended as an effective option of intensive treatment for refractory RA in the RA guidelines of the 2014 Asia-Pacific League of Associations for Rheumatology (APLAR) Conference (Ishiguro *et al.*, 2013).

*Corresponding author: e-mail: 13436156066@163.com

This study provided a medical basis for the clinical therapeutic options, by exploring the combined efficacy of MTX and IGU for female patients with moderate to severe RA and its impact on ovarian function.

MATERIALS AND METHODS

Study subjects

The 80 female patients diagnosed with moderate to severely active RA and enrolled in our department from Jan 2020 to Jan 2022 were selected as the study subjects. Inclusion criteria: (1) meet the RA classification criteria proposed by the 2009 American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR); (2) Age: 20-50 years old, with regular menstruation for nearly 3 months if under 40 years old (21-35 days as period, lasted for 2-7 days), and normal values of sex hormones in follicular phase tested on the 3rd day of period; (3) Never received drug treatment within half a year; (4) DAS28-ESR >3.2. Exclusion criteria: (1) history of confirmed ovarian cyst, polycystic ovary syndrome, endometriosis, ovarian surgery or radiation therapy and sex hormone therapy for other reasons; (2) history of contraceptives within half a year; (3) pregnancy and breastfeeding patients; (4) diagnosed with other basic diseases, such as diabetes and hypertension; (5) history of malignant tumors; (6) history of existing gynecological infectious diseases, such as pelvic inflammation. (7) MTX, IGU and meloxicam intolerance. The clinical trial was approved by the Hospital Ethics Committee and the subjects were all informed with consent.

Allocation

The 80 patients with moderate to severe active RA were randomly divided into MTX and MTX + IGU groups, with 40 patients in each group.

Research methods

Treatment

MTX group was treated with MTX + meloxicam 15mg qd. MTX + IGU group was treated with MTX + IGU 25 mg bid + meloxicam 15mg qd. The initial dose of MTX in both groups was 7.5mg qw, which was gradually increased 1 week later with a maximum of 15mg qw. Hydroxychloroquine was used as a remedy after 3 months.

Outcome measures

The swollen joint count (SJC), tender joint count (TJC), duration of morning stiffness and menstrual cycle were recorded at week 0 and week 24, respectively. The patients' erythrocyte sedimentation rate (ESR), rheumatoid factor (RF), high-sensitivity C-reactive protein (hsCRP), liver and kidney function, and cytokines (IL-6, TNF- α , etc.) were tested, and the DSA28-ESR score was calculated. On the 3rd day of period, ovarian reserve indicators (anti-Mullerian hormone in serum

(AMH), follicle stimulating hormone (FSH), luteotropic hormone (LH) and estradiol (E2)) were measured. The B ultrasound specialists measured antral follicle counting (AFC) and ovary volume (OV).

Ethical approval

This study involving human subjects was approved by the Affiliated Chongqing Chemical Industry Vocational College, Chongqing (with reference to the letter number AH-75-1883). Written informed consent has been signed by each participant.

STATISTICAL ANALYSIS

SPSS 22 was used to analyze data, with measurement data expressed as $x \pm s$ if normally distributed. Paired t-test was taken for comparison between before and after intervention. Those not conforming to normal distribution are expressed as median P50 (P25, P75), with Mann-Whitney U test for comparison between groups. $P < 0.05$ was considered to be statistically significant.

RESULTS

General data

A total of 80 female patients with RA were included, with age of 20-50 years old and mean age of 41.90 ± 7.95 years. The average disease course was 12.15 ± 10.16 months. The average SJC was 2.53 ± 0.67 and the average TJC was 5.66 ± 3.25 . The average duration of morning stiffness was 50.42 ± 42.45 min. The average ESR was 59.10 ± 19.59 mm/Hr, with median RF of 154 (47.68, 356) iu/ml. The average DSA28 score was 5.17 ± 0.38 . Patients randomized into 2 groups showed no statistical differences in age, disease course, STC, TJC, duration of morning stiffness, ESR, RF and DSA28 scores before treatment.

Follow-up data

Three months after the treatment, due to poor efficacy, 4 patients in the MTX group were treated with extra hydroxychloroquine and 0 in the MTX + IGU group was taken extra.

Comparison of efficacy between the 2 groups after treatment

(1) Comparison of clinical data: After treatment, the MTX + IGU group showed more obvious relief in SJC, TJC, ESR and DSA28-ESR score than MTX group. There are no significant differences between the two groups regarding morning stiffness duration or RF (fig. 1).

(2) Comparison of cytokines: After the treatment, both groups showed decreased levels of IL-1 β , IL-6, IL-17 and TNF- α compared to those before the treatment. The MTX + IGU group showed lower levels of IL-1 β , IL-6, IL-17, and TNF- α after treatment as compared to the MTX group (fig. 2).




Fig. 1: Comparison of clinical data. SJC, TJC, morning stiffness duration (min), ESR (mm/Hr), RF (iu/ml), and DSA28-ESR score in the MTX and MTX + IGU groups before and after treatment. *P<0.05, MTX + IGU group vs MTX group.




Fig. 2: Comparison of cytokines. IL-1 β , IL-6, IL-17 and TNF- α concentrations in the MTX and MTX + IGU groups before and after treatment. *P<0.05, MTX + IGU group vs MTX group.




Fig. 3: Comparison of ovarian function between the two groups. AMH (ng/ml), FSH (mIU/ml), E2 (pg/ml), LH (mIU/ml), AFC, and OV (cm³) in the MTX and MTX + IGU groups before and after treatment. *P<0.05, MTX + IGU group vs MTX group.

Comparison of ovarian functions between the 2 groups after treatment

Comparison of ovarian function between the 2 groups after treatment: There was no statistical difference in ovarian function between the 2 groups before treatment. After treatment, the MTX + IGU group showed increased AMH level compared to that before. No statistical difference was observed in AMH level before and after treatment in the MTX group. The MTX + IGU group showed significantly higher level of AMH than the MTX group. However, no statistical differences were observed in FSH, LH, E2, AFC, and OV levels between the two groups either before or after treatment (fig. 3).

DISCUSSION

The study has shown that IGU has few adverse effects for RA when used for treatment. A double-blind study (Ma *et al.*, 2014), which randomized 253 patients to IGU and placebo groups, found a ACR 20 response of 69.5% at week 24 in IGU group (30.7% in placebo group) and significant improvement in ACR 50 and ACR 70 responses, RF, Health Assessment Questionnaire Disability Index (HAQ-DI), and DAS28 scores after treatment, compared to those before. Another retrospective analysis of (Mok *et al.*, 2013) revealed that IGU has higher responder rate when used as treatment for elder RA patients than salazosulfapyridine (SASP), with more significant decline in RF and less adverse reaction.

With 36 months of follow-up, the retention rates of IGU group and SASP group were 52.4% and 32.1% respectively, with the responder rates of 85.8% and 65.2% and cumulative rates of any adverse event of 16.7 and 46.7% (Del *et al.*, 1989). The extra treatment of IGU for RA patients without enough response to MTX could enhance the ACR 20 response from 30.7% at week 24 to 72.1% at week 52 (Manger *et al.*, 2006). The combination therapy of IFU and MTX was considered to be not likely to significantly increase the incidence rate of adverse drug event (Hughes *et al.*, 2014). A total of 106 RA patients with IGU treatment combined with/without MTX were retrospectively observed and divided into MTX + IGU and IGU groups. Both groups showed significantly reduced DAS28-CRP from baseline, suggesting that IGU treatment may be a useful treatment option for those who cannot be treated with MTX (Boots *et al.*, 2013). Ebina *et al.* (2019) added IGU treatment to patients with inadequate responses to tocilizumab (TCZ), which turned out that 64.5% of them achieved a moderate response and 51.6% achieved ACR 20 at week 24.

It suggested that IGU treatment for patients with inadequate responses to TCZ may be a promising and safe complementary treatment option (Wang *et al.*, 2017). In this study, with female moderate to severe active RA patients as study subjects, the combination therapy of

MTX and IGU significantly relieved the SJC, TJC, ESR and DSA28-ESR scores at week 24 than MTX alone, with more obvious decrease in IL-6 and TNF- α levels of patients, suggesting the significant combined efficacy of MTX and IGU.

AMH, a hormone reflecting the remaining follicle pool and secreted by granulosa cells at reproductive ages used as a marker of ovarian reserve. Study (Hara *et al.*, 2014) demonstrated a significant reduction in AMH levels in premenopausal female RA patients, with lower levels in RA patients with positive CCP antibody, consistent with what described by Del Junco *et al.* (1989) that the RA patients have earlier age of menopause (Nozaki *et al.*, 2020). The reasons of the decreased fertility of female RA patients are considered to be related to RA itself, disease activity, age and drugs, with unknown specific mechanism. Sex hormones are involved in the pathogenesis and development process of RA. Estrogen promotes the onset of RA, whereas progesterone delays the onset of RA (Tanaka *et al.*, 2015). The changes in sex hormone levels during the onset and development of RA affect hypothalamic-pituitary-ovarianaxis through negative feedback and on the other hand, affect local multifactor regulation system, either of which may impact the ovarian reserve function in RA patients. About 20% of the patients with premature ovarian failure have ever had autoimmune diseases, and some patients have shown positive autoantibodies, including anti-ovary antibody, antinuclear antibodies, RF, anti cardiolipin antibody, anti zonapellucida antibody, etc. Earlier studies have found that female RA patients with positive RF and CCP antibodies had an earlier menstrual arrest without cytotoxic drugs, suggesting that autoimmune factors might lead to the exhausted (Xu *et al.*, 2015) of early follicles. Using a Cox regression analysis, Brouwer *et al.* (2019) concluded that age, labor absence, disease activity, and prepregnancy use of NSAIDs and prednisone were independent risk factors for prolonged pregnancy in female RA patients. In this study, patients with moderate to severe active RA were studied, with higher AMH levels in both groups after treatment than those before, suggesting that disease activity is one of the reasons of decreased ovarian reserve function in RA patients.

Antirheumatic drugs are the important causes of the impaired female fertility, especially the impaired ovarian reserve function. The study (Gan *et al.*, 2016) showed that SLE patients treated with CTX have significantly lower AMH levels compared with SLE patients without CTX, and that the AMH value is related to age and the accumulation of CTX use. Ovarian function is compromised by CTX and tripterygium glycosides use. MTX is considered the anchor drug (Fraenkel *et al.*, 2021) in treating rheumatoid arthritis patients but is proven to have side effect on the female reproductive system. Brouwer J *et al.* found significant difference in AMH

levels between RA patients treated with MTX at week 6 and those without. Brouwer *et al* also witnessed correlation between previous MTX use and its negative impact on pregnancy thereafter. Reproductive physician (Mizutani *et al.*, 2021) found differences in FSH or AFC before and after MTX treatment for eccyesis (both within and after 90 days of treatment) by comparing the ovarian reserve and ovarian reactivity during the subsequent IVF cycle. There were significant differences in the number of retrieved oocytes or the high-quality embryos transplanted, arguing that MTX would affect ovarian reserve, ovarian responsiveness, or IVF success in subsequent cycles.

There are no paper reporting the effect of MTX treatment combined with IGU on the female reproductive system. This study is the first to find that the combination therapy of MTX and IGU for female patients with moderate to severe active RA does not increase the negative impact on ovarian function, compared to MTX alone. On the contrary, AMH levels in patients are significantly increased after treatment compared with before, which may be related to better disease activity control.

CONCLUSION

The combination therapy of MTX and IGU has significantly better efficacy for female patients with moderate to severe active RA than MTX alone, with less impact on female ovarian function, and even improves ovarian reserve function in female patients through more effective control of RA activity.

REFERENCES

- Aikawa Y, Yamamoto M, Yamamoto T, Morimoto K and Tanaka K (2022). An anti-rheumatic agent T-614 inhibits NF-kappaB activation in LPS- and TNF-alpha-stimulated THP-1 cells without interfering with IkappaBalph degradation. *Inflamm. Res.*, **51**(4): 188-94.
- Asuka Inoue, Yuji Nozaki, Yasuaki Hirooka, Koji Kinoshita, Yasutaka Chiba, Masanori Funauchi and Itaru Matsumura (2020). The effectiveness and retention rate of iguratimod in Japanese rheumatoid arthritis patients with/without methotrexate in daily medical care. *Life (Basel)*, **10**(11): 463-515.
- Boots CE, Gustofson RL and Feinberg EC (2013). Does methotrexate administration for ectopic pregnancy after *in vitro* fertilization impact ovarian reserve or ovarian responsiveness? *Fertil. Steril.*, **100**(6): 1590-1593.
- Brouwer J, Laven JS, Hazes JM, Schipper I and Dolhain RJ (2013). Levels of serum anti-Müllerian hormone, a marker for ovarian reserve, in women with rheumatoid arthritis. *Arthritis Care Res. (Hoboken)*, **65**(9): 1534-8.
- Brouwer J, Hazes JM, Laven JS and Dolhain RJ (2015). Fertility in women with rheumatoid arthritis: Influence of disease activity and medication. *Ann. Rheum. Dis.*, **74**(10): 1836-1841.
- Brouwer J, Dolhain R, Hazes JMW, Visser JA and Laven JSE (2019). Reduced ovarian function in female rheumatoid arthritis patients trying to conceive. *ACR Open Rheumatol.*, **1**(5): 327-335.
- Clowse ME, Chakravarty E, Costenbader KH, Chambers C and Michaud K (2012). Effects of infertility, pregnancy loss and patient concerns on family size of women with rheumatoid arthritis and systemic lupus erythematosus. *Arthritis Care Res. (Hoboken)*, **64**(5): 668-674.
- Del Junco DJ, Annegers JF, Coulam CB and Luthra HS (1989). The relationship between rheumatoid arthritis and reproductive function. *Br. J. Rheumatol.*, **28**(Suppl 1): 33; discussion pp.42-45.
- Hughes GC and Choubey D (2014). Modulation of autoimmune rheumatic diseases by oestrogen and progesterone. *Nat. Rev. Rheumatol.*, **10**(12): 740-751.
- Ke Gan, Leilei Yang, Lingxiao Xu, Xiaoke Feng, Qiande Zhang, Fang Wang, Wenfeng Tan and Miaoqia Zhang (2016). Igaratimod (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264.7 cells via NF-κB and MAPK pathways. *Int Immunopharmacol.*, **35**(6): 294-300.
- Kosuke Ebina, Akira Miyama, Hideki Tsuboi, Shoichi Kaneshiro, Masataka Nishikawa, Hajime Owaki, Shigeyoshi Tsuji, Makoto Hirao, Yuki Etani, Atsushi Goshima, Jun Hashimoto and Hideki Yoshikawa (2019). The add-on effectiveness and safety of iguratimod in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab. *Mod. Rheumatol.*, **29**(4): 581-588.
- Liana Fraenkel, Joan M Bathon, Bryant R England, E William St Clair, Thurayya Arayssi, Kristine Carandang, Kevin D Deane, Mark Genovese, Kent Kwam Huston, Gail Kerr, Joel Kremer, Mary C Nakamura, Linda A Russell, Jasvinder A Singh, Benjamin J Smith, Jeffrey A Sparks, Shilpa Venkatachalam, Michael E Weinblatt, Mounir Al-Gibbawi, Joshua F Baker, Kamil E Barbour, Jennifer L Barton, Laura Cappelli, Fatimah Chamseddine, Michael George, Sindhu R Johnson, Lara Kahale, Basil S Karam, Assem M Khamis, Iris Navarro-Millán, Reza Mirza, Pascale Schwab, Namrata Singh, Marat Turgunbaev, Amy S Turner, Sally Yaacoub and Elie A Akl (2021). American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Rheumatol.*, **73**(7): 1108-1123.
- Littlejohn EA and Monrad SU (2018). Early diagnosis and treatment of rheumatoid arthritis. *Prim. Care*, **45**(2): 237-255.
- Ma M, Chen XY, Gu C, Xiao XR, Guo T and Li B (2014). Biochemical changes of oxidative stress in premature ovarian insufficiency induced by tripterygium glycosides. *Int. J. Clin. Exp. Pathol.*, **7**(12): 8855-8861.
- Manger K, Wildt L, Kalden JR and Manger B (2006).

- Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: The PREGO-Study. *Autoimmun Rev.*, **5**(4): 269-72.
- Masako Hara, Tohru Abe, Sachiko Sugawara, Yutaka Mizushima, Keiko Hoshi, Shoichiro Irimajiri, Hiroshi Hashimoto, Shinichi Yoshino, Nobuo Matsui, Masashi Nobunaga, Shigeyuki Nakano (2007). Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: A controlled, multicenter, double-blind, parallel-group study. *Mod. Rheumatol.*, **17**(1): 1-9.
- Masako Hara, Naoki Ishiguro, Kou Katayama, Masakazu Kondo, Takayuki Sumida, Tsuneyo Mimori, Satoshi Soen, Kota Nagai, Tomonobu Yamaguchi, Kazuhiko Yamamoto and Iguratimod-Clinical Study Group (2014). Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: An open-label extension of a randomized, double-blind, placebo-controlled trial. *Mod. Rheumatol.*, **24**(3): 410-418.
- Melanie Henes, Julia Froeschlin, Florin A Taran, Sara Brucker, Kristin K Rall, Theodoros Xenitidis, Annette Igney-Oertel, Barbara Lawrenz and Joerg C Henes (2015). Ovarian reserve alterations in premenopausal women with chronic inflammatory rheumatic diseases: Impact of rheumatoid arthritis, Behçet's disease and spondyloarthritis on anti-Müllerian hormone levels. *Rheumatology (Oxford)*, **54**(9): 1709-1712.
- Mizutani S, Kodera H, Sato Y, Nanki T, Yoshida S and Yasuoka H (2021). Clinical effectiveness of iguratimod based on real-world data of patients with rheumatoid arthritis. *Clin. Rheumatol.*, **40**(1): 123-132.
- Mok CC, Chan PT and To CH (2013). Anti-müllerian hormone and ovarian reserve in systemic lupus erythematosus. *Arthritis Rheum.*, **65**(1): 206-210.
- Naoki Ishiguro, Kazuhiko Yamamoto, Kou Katayama, Masakazu Kondo, Takayuki Sumida, Tsuneyo Mimori, Satoshi Soen, Kota Nagai, Tomonobu Yamaguchi, Masako Hara and Iguratimod-Clinical Study Group (2013). Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: A randomized, double-blind, placebo-controlled trial. *Mod. Rheumatol.*, **23**(3): 430-439.
- Nozaki Y (2021). Iguratimod: Novel molecular insights and a new csDMARD for rheumatoid arthritis, from Japan to the World. *Life (Basel)*, **11**(5): 276-304.
- Nozaki Y, Inoue A, Kinoshita K, Funauchi M and Matsumura I (2020). Efficacy of iguratimod vs. salazosulfapyridine as the first-line csDMARD for rheumatoid arthritis. *Mod. Rheumatol.*, **30**(2): 249-258.
- Practice Committee of the American Society for Reproductive Medicine (2020). Electronic address: asrm@asrm.org; Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: A committee opinion. *Fertil Steril.*, **114**(6): 1151-1157.
- Tanaka K, Yamaguchi T and Hara M (2015). Iguratimod for the treatment of rheumatoid arthritis in Japan. *Expert Rev. Clin. Immunol.*, **11**(5): 565-73.
- Tanaka K, Yamamoto T, Aikawa Y, Kizawa K, Muramoto K, Matsuno H and A Muraguchi (2003). Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice. *Rheumatology (Oxford)*, **42**(11): 1365-1371.
- Wang X, Ma C, Li P, Zhao F and Bi L (2017). Effects of iguratimod on the levels of circulating regulators of bone remodeling and bone remodeling markers in patients with rheumatoid arthritis. *Clin. Rheumatol.*, **36**(6): 1369-1377.
- Xu Y, Zhu Q, Song J, Liu H, Miao Y and Yang F, Wang F, Cheng W, Xi Y, Niu X, He D and Chen G (2015). Regulatory effect of iguratimod on the balance of the subsets and inhibition of inflammatory cytokines in patients with rheumatoid arthritis. *Mediators Inflamm.*, 356040.
- Yan Ye, Mei Liu, Longhai Tang, Fang Du, Yuanhua Liu, Pei Hao, Qiong Fu, Qiang Guo, Qingran Yan, Xiaoming Zhang and Chunde Bao (2019). Iguratimod represses B cell terminal differentiation linked with the inhibition of PKC/EGR1 axis. *Arthritis Res. Ther.*, **21**(1): 92.
- Zheng N, Guo C and Wu R (2018). Iguratimod is effective in refractory rheumatoid arthritis patients with inadequate response to methotrexate-cyclosporin A-hydroxychloroquine-prednisone. *Scand J. Rheumatol.*, **47**(5): 422-424.